Literature DB >> 25215472

Inflammatory response in Parkinson's disease (Review).

Junqiang Yan1, Qizhi Fu1, Liniu Cheng1, Mingming Zhai1, Wenjuan Wu1, Lina Huang1, Ganqin Du1.   

Abstract

Parkinson's disease (PD) is one of the most common age‑related neurodegenerative diseases, which results from a number of environmental and inherited factors. PD is characterized by the slow progressive degeneration of dopaminergic (DA) neurons in the substantia nigra. The nigrostriatal DA neurons are particularly vulnerable to inflammatory attack. Neuroinflammation is an important contributor to the pathogenesis of age‑related neurodegenerative disorders, such as PD, and as such anti‑inflammatory agents are becoming a novel therapeutic focus. This review will discuss the current knowledge regarding inflammation and review the roles of intracellular inflammatory signaling pathways, which are specific inflammatory mediators in PD. Finally, possible therapeutic strategies are proposed, which may downregulate inflammatory processes and inhibit the progression of PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25215472     DOI: 10.3892/mmr.2014.2563

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  33 in total

Review 1.  Neural immune modulation and immunotherapy assisted by focused ultrasound induced blood-brain barrier opening.

Authors:  Pin-Yuan Chen; Kuo-Chen Wei; Hao-Li Liu
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

2.  Linalool Inhibits LPS-Induced Inflammation in BV2 Microglia Cells by Activating Nrf2.

Authors:  Yang Li; Ou Lv; Fenggang Zhou; Qingsong Li; Zhichao Wu; Yongri Zheng
Journal:  Neurochem Res       Date:  2015-06-04       Impact factor: 3.996

Review 3.  HIV-associated cellular senescence: A contributor to accelerated aging.

Authors:  Justin Cohen; Claudio Torres
Journal:  Ageing Res Rev       Date:  2016-12-23       Impact factor: 10.895

4.  Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.

Authors:  Rosa Calvello; Antonia Cianciulli; Giuseppe Nicolardi; Francesco De Nuccio; Laura Giannotti; Rosaria Salvatore; Chiara Porro; Teresa Trotta; Maria Antonietta Panaro; Dario Domenico Lofrumento
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-16       Impact factor: 4.147

Review 5.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

Review 6.  Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?

Authors:  Bianca Guglietti; Srisankavi Sivasankar; Sanam Mustafa; Frances Corrigan; Lyndsey E Collins-Praino
Journal:  Mol Neurobiol       Date:  2021-08-25       Impact factor: 5.590

7.  Effects of Toxoplasma gondii on Levels of Interleukin-5 in Parkinson's Patients.

Authors:  S Hasan Kadhum Al-Huchaimi; G Hameed Neamah Al-Kefaei; B Ahmed Alameedy
Journal:  Arch Razi Inst       Date:  2022-02-28

Review 8.  Research progress on the relationship between chronic periodontitis and Parkinson's disease.

Authors:  Mengyao Bian; Lili Chen; Lihong Lei
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

Review 9.  Neuroinflammatory responses in Parkinson's disease: relevance of Ibuprofen in therapeutics.

Authors:  Ashish Singh; Pratibha Tripathi; Sarika Singh
Journal:  Inflammopharmacology       Date:  2020-10-14       Impact factor: 4.473

10.  Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.

Authors:  Anamitra Ghosh; Monica R Langley; Dilshan S Harischandra; Matthew L Neal; Huajun Jin; Vellareddy Anantharam; Joy Joseph; Timothy Brenza; Balaji Narasimhan; Arthi Kanthasamy; Balaraman Kalyanaraman; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-02       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.